Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib plus rituximab and bendamustine versus placebo plus rituximab and bendamustine in previously treated indolent non-Hodgkin lymphoma
2015-004033-28Phase 3Terminated
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in indolent lymphoma comparing Duvelisib + rituximab + bendamustine with Placebo + rituximab + bendamustine (2 arms). Primary endpoint: Progression-free survival. Started Jan 2016; status: terminated.
02
Drugs
duvelisib
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on 2015-004033-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004033-28.